Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of BT-007 CAR-T Cells in the Treatment of Patients With Relapsed/Refractory T Cell Lymphoblastic Lymphoma (R/R T-LBL)

NCT05554575 is registered in ClinicalTrials.gov with Bioceltech Therapeutics, Ltd. as lead sponsor.

NCT NCT05554575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05554575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of BT-007 CAR-T Cells in the Treatment of Patients With Relapsed/Refractory T Cell Lymphoblastic Lymphoma (R/R T-LBL)
Lead sponsor
Bioceltech Therapeutics, Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
October 31, 2022
Completion date
September 30, 2024
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

t cell lymphoblastic lymphoma